Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · KALA BIO, Inc. (KALA)

KALA BIO signs exclusive U.S. distribution deal with Virotek for eye genetic testing

Neutral Impact 3 of 5 product/contract Written later

KALA BIO entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc. on September 3, 2026, appointing Kala as sole distributor and reseller in the United States of a genetic testing and screening program for ophthalmology. Net profit from the program is split equally after Virotek recovers cost of goods sold, and the filing does not disclose any upfront payment or financial projections for the deal.

Key points

  • Agreement dated September 3, 2026 with Virotek, a Wyoming corporation; initial term of five years
  • Exclusivity converts to non-exclusive if Kala misses a milestone in Exhibit B by September 3, 2027, after a 30-day cure period
  • Net profit split equally between Virotek and Kala after cost of goods sold is recovered by Virotek
  • Virotek granted Kala a right of first refusal on certain dispositions of ophthalmological products, with at least 30 days to exercise

The filing

CompanyKALA BIO, Inc. (KALA)
Form8-K, current report
Filed with the SECSep 10, 2026, 5:24 PM ET
Accession number0001829126-26-009999

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.